**ARCA BIOPHARMA TO PRESENT AT THE SIDOTI & COMPANY FALL 2017 CONFERENCE**

*Westminster, CO, September 21, 2017* – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it will present a corporate overview at the Sidoti & Company Fall 2017 Conference, taking place September 28, 2017 in New York, New York.

**Date:** Thursday, September 28, 2017
**Time**: 3:40 p.m. (Eastern Time)
**Presenter**: Thomas Keuer, Chief Operating Officer
**Webcast/Presentation**: The live webcast will be available at http://www.investorcalendar.com/event/20225 and http://arcabio.com/investors/investor-presentations/. ARCA's corporate investor presentation will be posted in the Investor Relations section of its website (www.arcabio.com).
**Replay Information**: A replay of the webcast is expected to be available approximately two hours after the presentation on September 28, 2017, and will remain available for 90 days. The replay can be accessed at http://www.investorcalendar.com/event/20225.

**About ARCA biopharma**

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, Gencaro™ (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of patients with atrial fibrillation and HFrEF, currently in a Phase 2B clinical trial. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. The Gencaro development program has been granted Fast Track designation by the FDA. For more information, please visit www.arcabio.com.

**Safe Harbor Statement**

*This press release and the anticipated presentation contain "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995.*

*These statements include, but are not limited to, statements regarding, the potential timeline for GENETIC-AF trial activities, potential timing for the announcement of topline data for the Phase 2B GENETIC-AF trial, the sufficiency of ARCA's capital to support its operations, the expected features and characteristics of Gencaro, including the potential for genetic variations to predict individual patient response to Gencaro, Gencaro's potential to treat AF, future treatment options for patients with AF, and the potential for Gencaro to be the first genetically-targeted AF prevention treatment. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA's financial resources and whether they will be sufficient to meet its business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA's intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA's filings with the Securities and Exchange Commission, including without limitation ARCA's annual report on Form 10-K for the year ended December 31, 2016, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.*

**Investor & Media Contact:**
Derek Cole
720.940.2163
derek.cole@arcabio.com

###